DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DF-6002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DF-6002 overview

BMS-986415 (DF-6002) is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma , classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, ovarian cancer, prostate cancer, esophageal cancer, cervical cancer, hepatocellular cancer, Merkel cell carcinoma, renal cell carcinoma, endometrial cancer, cutaneous T cell lymphoma or triple-negative breast cancer. It is a monovalent human interleukin-12 (IL12)-constant fragment (Fc) fusion protein, administered through the subcutaneous route. The drug candidate acts by targeting IL12 receptor.

Dragonfly Therapeutics overview

Dragonfly Therapeutics (Dragonfly) is a clinical-stage biotechnology company. It discovers, develops, and commercializes novel immune therapies to treat autoimmune disease, oncology, neuro-inflammation, and others. The company utilizes its novel TriNKET and CYTOKINE platforms for developing its pipeline products which include DF1001,DF5100, DF8203, DF8500, DF6002, DF9001, and DF6215 drug candidates for the treatment of solid tumors, breast cancer, autoimmune diseases, fibrotic diseases and others. Dragonfly is also developing various other drug candidates for in collaboartion with companies such as Bristol Myers Squib, Merck, AbbVie, and Gilead. Dragonfly is headquartered in Waltham, Massachusetts, the US.

For a complete picture of DF-6002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.